文献速递细菌感染、耐药与抗菌药物

亚胺培南/瑞来巴坦与头孢洛扎/他唑巴坦对难治耐药和多药耐药革兰阴性杆菌的体外活性:美国2015-2017年监测研究

In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.
PubMed 文献 · Clin Infect Dis · 2021-01-01

结果显示,肠杆菌目中DTR占1.0%、MDR占15.6%;铜绿假单胞菌中DTR占8.4%、MDR占32.4%。亚胺培南/瑞来巴坦对多数DTR和MDR菌株保持体外活性,头孢洛扎/他唑巴坦对铜绿假单胞菌DTR和MDR菌株也有较好活性。

要点

  • 肠杆菌目中DTR占1.0%、MDR占15.6%;铜绿假单胞菌中DTR占8.4%、MDR占32.4%。
  • ICU和非ICU相比、呼吸道与腹腔/尿路相比,MDR及DTR率显著更高(P < .05)。
  • 亚胺培南/瑞来巴坦对82.4%的DTR和92.1%的MDR肠杆菌目、62.2%的DTR和82.2%的MDR铜绿假单胞菌敏感。

核心结论

  • MDR表型可能高估革兰阴性杆菌中限制治疗的耐药性。
  • 美国DTR肠杆菌目不常见,而MDR肠杆菌目以及DTR和MDR铜绿假单胞菌常见。
  • 亚胺培南/瑞来巴坦对肠杆菌目和铜绿假单胞菌、头孢洛扎/他唑巴坦对铜绿假单胞菌的多数DTR和MDR分离株保持体外活性。

研究设计与样本

  • 研究采用CLSI定义的肉汤微量稀释法测定MIC。

主要发现

  • 肠杆菌目中1.0%为DTR、15.6%为MDR;铜绿假单胞菌中8.4%为DTR、32.4%为MDR。
  • ICU分离株的MDR率(肠杆菌目和铜绿假单胞菌)及DTR率(铜绿假单胞菌)显著高于非ICU(P < .05)。
  • 呼吸道分离株的MDR率(肠杆菌目和铜绿假单胞菌)及DTR率(铜绿假单胞菌)显著高于腹腔或尿路分离株(P < .05)。
  • 肠杆菌目中,82.4%的DTR和92.1%的MDR对亚胺培南/瑞来巴坦敏感,1.5%的DTR和65.8%的MDR对头孢洛扎/他唑巴坦敏感。
  • 铜绿假单胞菌中,62.2%的DTR和82.2%的MDR对亚胺培南/瑞来巴坦敏感,67.5%的DTR和84.0%的MDR对头孢洛扎/他唑巴坦敏感。

关键数值与推荐

  • MDR定义采用Magiorakos等(Clin Microbiol Infect 2012;18:268-81)的标准。
  • DTR定义采用Kadri等(Clin Infect Dis 2018;67:1803-14)的标准,聚焦对一线药物(所有β-内酰胺类和氟喹诺酮类)的限制治疗耐药。
  • MIC采用CLSI定义的肉汤微量稀释法测定。

临床怎么用

  • 临床微生物实验室可报告DTR表型以更准确反映治疗限制性耐药。
  • 对碳青霉烯类耐药肠杆菌目和铜绿假单胞菌感染,亚胺培南/瑞来巴坦和头孢洛扎/他唑巴坦可作为体外有活性的治疗选择参考。
  • ICU和呼吸道标本分离的革兰阴性杆菌耐药率更高,经验性治疗需考虑覆盖耐药菌。

局限性

  • 研究仅纳入美国26家医院2015-2017年的分离株,外推需谨慎。
  • 仅评估体外敏感性,未结合临床结局或用药剂量。
  • 未报告非发酵菌中其他菌种的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multidrug-resistant (MDR) bacteria are frequently defined using the criteria established by Magiorakos et al [Clin Microbiol Infect 2012;18:268-81]. Difficult-to-treat resistance (DTR) [Kadri et al, Clin Infect Dis 2018;67:1803-14] is a novel approach to defining resistance in gram-negative bacilli focusing on treatment-limiting resistance to first-line agents (all β-lactams and fluoroquinolones). METHODS: Clinical and Laboratory Standards Institute-defined broth microdilution minimum inhibitory concentrations (MICs) were determined for imipenem/relebactam, ceftolozane/tazobactam, and comparators against respiratory, intraabdominal, and urinary isolates of Enterobacterales (n = 10 516) and Pseudomonas aeruginosa (n = 2732) collected in 26 US hospitals in 2015-2017. RESULTS: Among all Enterobacterales, 1.0% of isolates were DTR and 15.6% were MDR; 8.4% of P. aeruginosa isolates were DTR and 32.4% were MDR. MDR rates for Enterobacterales and DTR and MDR rates for P. aeruginosa were significantly higher (P < .05) in isolates collected in intensive care units (ICUs) than in non-ICUs and in respiratory tract isolates than in intraabdominal or urinary tract isolates. In addition, 82.4% of DTR and 92.1% of MDR Enterobacterales and 62.2% of DTR and 82.2% of MDR P. aeruginosa were imipenem/relebactam-susceptible, and 1.5% of DTR and 65.8% of MDR Enterobacterales and 67.5% of DTR and 84.0% of MDR P. aeruginosa were ceftolozane/tazobactam-susceptible. CONCLUSIONS: MDR phenotypes defined using the Magiorakos criteria may overcall treatment-limiting resistance in gram-negative bacilli. In the US, DTR Enterobacterales were infrequent, while MDR Enterobacterales isolates and DTR and MDR P. aeruginosa were common. Imipenem/relebactam (Enterobacterales, P. aeruginosa) and ceftolozane/tazobactam (P. aeruginosa) retained in vitro activity against most DTR and MDR isolates.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Karlowsky JA, Lob SH, Raddatz J, et al. In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017. Clin Infect Dis. 2021. PMID: 32246147. doi:10.1093/cid/ciaa381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。